What Happens When Pharmaceutical Companies Listen to Patients?

What I've seen and heard in the room when patients and pharma executives sit down together

When you read a clinical trial consent form, a patient information leaflet, or recruitment materials for a study, you’re almost certainly not seeing the first draft.

In fact, you’re probably seeing version 5, or 8, or 12, rewritten after patients said the original was incomprehensible, overwhelming or completely missed what actually mattered to them.

At least, that’s what happens when pharmaceutical companies do it right.

More and more pharma companies (although far from all) are engaging patients in shaping their communications. There are now rankings of pharmaceutical companies based on their interactions with patients—initiatives like PatientView’s Corporate Reputation survey that specifically evaluate patient engagement practices.

This process—where patients review, challenge and help shape health messaging before it reaches you—is happening more than it used to.

And it should be happening even more.

---

I've been writing about health for over a decade. The juiciest details live behind the paywall.

---

What are patient advocacy meetings?

Patient advocacy meetings are structured sessions where pharmaceutical companies consult patients, caregivers and advocacy group representatives.

This is where a lot of health messaging gets tested and reshaped before you see it. And the best companies go beyond just consulting with patients—they practice what’s called co-creation, where patients are involved from the beginning in developing materials, not just reviewing them at the end.

That’s when you see the biggest difference in quality and clarity.

I know this because attending, reporting on, and producing outputs from these meetings is one of my specialisms as a medical writer.

Over the past decade, I’ve attended hundreds of such meetings (probably more, I’ve lost count)—sometimes 10-15 different meetings a year, both virtual and in-person. I’ve worked with patients from many different communities, getting to know some of them over numerous years.

I’ve watched patients flag jargon that makes no sense, call out assumptions that don’t reflect reality, and push back on messaging that prioritises what pharma wants to say over what patients need to hear.

I’ve documented those conversations and turned them into reports that reshape communication strategies.

I hope that understanding this process will help you read pharmaceutical communication more critically—and spot the difference between messaging that’s genuinely been shaped by patient input versus messaging that simply claims to be ‘patient-focused.’

So, here’s how it works when it’s done well—and what to look for when it’s not.

What Gets Reviewed and Revised in These Meetings (When Companies Do This Right)

A huge part of what happens when companies genuinely engage patients is reviewing and revising how information gets communicated to patients and the public.

Some do this consistently and well, involving patients early and often. Some do it minimally, checking boxes for compliance. Some don’t do it at all. But the companies that do this well understand that patient input improves not just their communication, but their outcomes.

Here’s what patients and caregivers might be looking at:

• Consent forms and patient information sheets. Patients read through drafts and flag medical jargon that doesn’t make sense, sections that feel overwhelming, assumptions that don’t reflect their reality, or information that’s missing but crucial.

• Trial recruitment materials, or the language used to invite patients into studies, the way risks and benefits are explained, what gets emphasised and what gets minimised. Patients review these and say: “This makes it sound scarier than it is,” or “You’re not being clear about what participation actually involves.”

• Patient-facing communications about results. When clinical trial results are ready to be shared, patients might review how they’re being explained. Is the language accessible? Are the limitations clear?

• Educational materials and disease awareness content, which are resources that explain conditions, treatment options, or how to manage side effects. Patients identify what’s missing, what’s confusing, what assumptions are being made about health literacy or access to care.

• ‘Patient-centric’ messaging. When pharmaceutical companies talk about being patient-focused, patients are often reviewing that language. Does it reflect reality? Does it align with how patients actually experience the company’s products and programs?

Let me show you a concrete example of what this could look like in practice.

A pharmaceutical company drafts a consent form for a clinical trial. It’s thorough, legally vetted, and full of phrases like “potential adverse events of moderate to severe intensity.”

A patient reads it and shares with the group: “I have no idea what this means or how worried I should be.”

The revised version used plain language, specific examples of what side effects might actually feel like, and clear instructions for when to call the study team.

How to Spot When Materials Have (Or Haven’t) Been Informed by Patient Input

Now that you know this process exists—and that not all companies do it equally well or at all—you can start evaluating pharmaceutical communication more critically.

Here’s what to look for:

• Language that sounds human. If a patient information leaflet reads like it was written by a lawyer for lawyers, patients probably didn’t review it, or their feedback wasn’t taken into account. If it uses plain language and anticipates real questions, they probably did.

• Practical information up front. Materials shaped by patient input tend to lead with what patients want to know first: What will this involve? How long will it take? What are my options?

• Acknowledgment of real barriers and limitations. Patient-informed communication might be more honest about challenges, uncertainties and what we don’t know yet.

• Diverse representation. When patient advocacy groups with diverse membership have been involved, you’ll see communication that reflects different communities, languages, health literacy levels, and access to care.

The Growing Trend (And Why It Needs to Keep Growing)

The good news is: patient engagement within pharmaceutical communication is increasing.

More companies are establishing patient advisory boards, involving patients earlier in the process, and moving toward co-creation models.

But we’re not there yet. Many companies still:

• Consult patients too late in the process to make meaningful changes.

• Limit patient engagement to specific therapeutic areas while ignoring it in others.

• Involve the same small group of “professional patients” rather than seeking truly diverse perspectives.

• Treat patient feedback as advisory rather than essential.

• Do not invest in building long-term relationships with patient communities.

But patient engagement should be standard practice. Every patient-facing communication should be shaped by the people it’s meant to serve. Every pharmaceutical company should be investing in meaningful, ongoing relationships with patient communities—not just when they need something, but as a core part of how they operate.

The pharmaceutical industry creates mountains of patient-facing communication: consent forms, information leaflets, recruitment materials, educational resources, results announcements.

The quality and clarity of those materials depends heavily on whether patients were in the room shaping them from the beginning, and whether pharma teams actually listened.

The more this becomes standard, the better the health information you receive will be. The more patients, advocates, and the public demand it, the more it will become standard practice rather than a competitive differentiator.

---

This is part of my Make Sense series, where I help you understand how health information is communicated—so you can navigate it more critically and make better-informed decisions.

Want the BS detector toolkit? Paid subscribers get the downloadable NO BS Health Claims Checklist—red flags, green flags, and questions to ask before believing any health claim.

[ —> Get my NO BS Checklist for Spotting Dodgy Health Claims]